- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01687257
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Newtown, New South Wales, Australia
-
-
-
-
-
Barcelona, España
-
-
Madrid
-
Majadahonda, Madrid, España
-
-
-
-
Colorado
-
Aurora, Colorado, Estados Unidos
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos
-
-
-
-
Clichy
-
Leclerc, Clichy, Francia
-
-
-
-
Auckland
-
Grafton, Auckland, Nueva Zelanda
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Chronic infection with Hepatitis C with HCV RNA > 1000 IU/mL
- Individuals with cirrhosis with Child-Pugh score < 10
- Esophageal or gastric varices on endoscopy within 6 months prior to or at screening
- Hepatic Venous Pressure Gradient (HVPG) > 6 mmHg
- Body mass index (BMI) ≥ 18 kg/m^2
- Naïve to all nucleotides/nucleoside treatments for chronic HCV infection
Exclusion Criteria:
- Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance
- HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive)
- Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the last 6 months or during screening
- Refractory ascites as defined by requiring paracentesis > twice within 1 month prior to screening
- Active variceal bleeding within 6 months of screening
- Expected survival of < 1 year
- History of hepatorenal, or hepatopulmonary syndrome.
- Evidence of renal impairment (CrCl < 50 mL/min)
- History of major organ transplantation, including liver transplant.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: SOF+RBV
Participants will receive SOF+RBV for 48 weeks.
|
Comprimidos de RBV administrados por vía oral en una dosis diaria dividida de acuerdo con las recomendaciones de dosificación basadas en el peso del prospecto (< 75 kg = 1000 mg y ≥ 75 kg = 1200 mg)
SOF 400 mg comprimido administrado por vía oral una vez al día
Otros nombres:
|
|
Experimental: Observation, then SOF+RBV
Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
|
Comprimidos de RBV administrados por vía oral en una dosis diaria dividida de acuerdo con las recomendaciones de dosificación basadas en el peso del prospecto (< 75 kg = 1000 mg y ≥ 75 kg = 1200 mg)
SOF 400 mg comprimido administrado por vía oral una vez al día
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
Periodo de tiempo: Posttreatment Week 12 (SOF+RBV) and up to 24 weeks (Observation)
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.
For the Observation/SOF+RBV group, SVR12 during the observational period was defined as HCV RNA < LLOQ for 12 consecutive weeks, any time during the observational period.
|
Posttreatment Week 12 (SOF+RBV) and up to 24 weeks (Observation)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants With SVR at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)
Periodo de tiempo: Posttreatment Weeks 4, 24, and 48
|
SVR4, SVR24, and SVR48 were defined as HCV RNA < LLOQ at 4, 24, and 48 weeks after stopping study treatment, respectively.
|
Posttreatment Weeks 4, 24, and 48
|
|
Percentage of Participants Experiencing On-Treatment Virologic Failure
Periodo de tiempo: Up to 48 weeks
|
On-treatment virologic failure was defined as:
|
Up to 48 weeks
|
|
Percentage of Participants Experiencing Viral Relapse
Periodo de tiempo: Up to Posttreatment Week 24
|
Viral relapse was defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.
|
Up to Posttreatment Week 24
|
|
Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at End of Treatment
Periodo de tiempo: Baseline; Week 24 (Observation) and Week 48 (SOF+RBV)
|
HVPG closely reflects the degree of portal hypertension in patients with cirrhosis.
The end of treatment for the Observation group was defined as the end of the observation period.
The treatment period for Group 2 was defined as the end of the observation period to the end of the treatment.
Baseline values were the last available values on or prior to first dose date of any study drug.
|
Baseline; Week 24 (Observation) and Week 48 (SOF+RBV)
|
|
Change From Baseline in Child-Pugh-Turcotte (CPT) Score
Periodo de tiempo: Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. Data are presented as improvement, no change, or worsening in CPT scores at Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV groups). Improvement in CPT score was defined as having a decrease in CPT score from baseline, no change in CPT score was defined as having no change in CPT score from baseline, and worsening in CPT score was defined as having an increase in CPT score from baseline. Baseline values were the last available values on or prior to first dose date of any study drug. |
Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
|
Change From Baseline in Model for End Stage Liver Disease (MELD) Scores
Periodo de tiempo: Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. Data are presented as improvement, no change, or worsening in MELD scores at Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV groups). Improvement in MELD score was defined as having a baseline MELD score of 11-15 or 16-20 that changed to 0-10, or a baseline MELD score of 16-20 that changed to 11-15; no change in MELD score was defined as having no change in score group (0-10, 11-15, or 16-20) from baseline; and worsening in MELD score was defined as having a baseline MELD score of 0-10 that changed to 11-15 or 16-20, or a baseline MELD score of 11-15 that changed to 16-20. Baseline values were the last available values on or prior to first dose date of any study drug. |
Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Insuficiencia hepática
- Procesos Patológicos
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades del HIGADO
- Infecciones por Flaviviridae
- Hepatitis, Viral, Humana
- Hepatitis
- Fibrosis
- Hipertensión
- Insuficiencia hepática
- Hepatitis C
- Cirrosis hepática
- Hipertensión Portal
- Agentes antiinfecciosos
- Agentes Antivirales
- Sofosbuvir
Otros números de identificación del estudio
- GS-US-334-0125
- 2012-002457-29 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .